Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Preclinical Characterization of the Anti-Leukemia Activity of the CD33/CD16/NKG2D Immune Modulating TriNKET ® BMS-986357 (CC-96191)

Margaret C. Lunn, George S. Laszlo, Sarah Eraiss, Mark T. Orr, Heidi K. Jessup, Henry Chan, Heather J. Thomas, Ann F. Cheung, Gregory P. Chang, Asya Grinberg, Eduardo Rodríguez-Arbolí, Sheryl Y. T. Lim, Allie R. Kehret, Jenny Huo, Frances M. Cole, Samuel C. Scharffenberger, Roland B. Walter

Blood (2023) 142 (Supplement 1): 1431.

https://doi.org/10.1182/blood-2023-185432

Published: 2023

Journal Articles

Efficacy and Safety of Single-Agent Zandelisib Administered By Intermittent Dosing in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Final Results of the Tidal Phase 2 Study

Andrew D. Zelenetz, Wojciech Jurczak, Vincent Ribrag, Kim M. Linton, Graham P. Collins, Mark Bishton, Javier López Jiménez, Bhagirathbhai Dholaria, Andrea Mengarelli, Tycel J. Phillips, Nagendra Prasad Sungala, Henry Chan, Gerardo Musuraca, Oonagh Sheehy, Junyi Yan, Weiming Xu, Michel Azoulay, Pier Luigi Zinzani

Blood (2022) 140 (Supplement 1): 3595–3597.

https://doi.org/10.1182/blood-2022-165409

Published: 2022

Journal Articles

Real World Comparison of Treatment Outcomes for Myeloma in Elderly Transplant-Ineligible Population with RVD, RD and VCD in Frontline Setting: Results from Mrdr Australia and New Zealand

Sarah Zhao, Cameron Wellard, Zoe McQuilten, Elizabeth M. Moore, Erica M. Wood, Andrew Spencer, Henry Chan

Blood (2022) 140 (Supplement 1): 10007–10008.

https://doi.org/10.1182/blood-2022-165109

Published: 2022

Journal Articles

Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial

Blood (2022) 140 (Supplement 1): 573–576.

https://doi.org/10.1182/blood-2022-163371

Published: 2022

Journal Articles

A Phase 1 Study with the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination with Zanubrutinib (ZANU) in Patients (Pts) with Non-Hodgkin Lymphoma (NHL) or Waldenström Macroglobulinemia (WM): Preliminary Data

Jacob D. Soumerai, Masa Lasica, Stephen Opat, Chan Y. Cheah, Henry Chan, Emma Verner, Eva González Barca, Alessandra Tedeschi, James Hilger, Yiqian Fang, David Simpson, Constantine S. Tam

Blood (2022) 140 (Supplement 1): 9325–9327.

https://doi.org/10.1182/blood-2022-169664

Published: 2022

Journal Articles

SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine + Rituximab (BR) in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Blood (2021) 138 (Supplement 1): 396.

https://doi.org/10.1182/blood-2021-148457

Published: 2021

Journal Articles

Discovery and Preclinical Characterization of CC-95251, an Anti-SIRPα Antibody That Enhances Macrophage-Mediated Phagocytosis of Non-Hodgkin Lymphoma (NHL) Cells When Combined with Rituximab

Henry Chan, Christina Trout, David Mikolon, Preston Adams, Roberto Guzman, Gustavo Fenalti, Konstantinos Mavrommatis, Mahan Abbasian, Lawrence Dearth, Brian Fox, Pallavur Sivakumar, Kandasamy Hariharan

Blood (2021) 138 (Supplement 1): 2271.

https://doi.org/10.1182/blood-2021-147262

Published: 2021

Journal Articles

Efficacy and Tolerability of Gemcitabine-Based Chemotherapy in Relapsed/Refractory Lymphoma Patients Not Eligible for Stem Cell Transplant

May Chiu, Samuel Hague, Henry Chan

Blood (2021) 138 (Supplement 1): 4566.

https://doi.org/10.1182/blood-2021-149810

Published: 2021

Journal Articles

Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Follow-up Results from Arm C of the SEQUOIA (BGB-3111-304) Trial

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-134280

Published: 2020

Journal Articles

Conservative Management of Hemochromatosis without Long-Term Maintenance Venesections in Patients with Moderate Iron Burden

Jenny Sumin Yoon, MBChB, Ross Alistair Henderson, MBChB FRACP FRCPA PhD, Merit Hanna, MBChB FRCPA, Eileen Merriman, MBChB BMLSc FRACP FRCPA PhD, Anna Elinder, MBChB FRACP FRCPA, Gilly Selman, MLS, Leone Kennedy, BN PGCertHSc, Henry Chan, MBChB, FRACP, FRCPA

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-136534

Published: 2020

Journal Articles

Bortezomib Induction and Consolidation in Patients with Multiple Myeloma Who Received Frontline Autologous Stem Cell Transplant

Sarah Ai Ting Tan, Steven Shih, MBChB, Scarlett Olasope, MBChB, Sharon R. Jackson, FRACP, FRCPA, Sarah Poplar, MBChB,FRCPath,FRPATH,PGCert,MRCP,ClinEd, Henry Chan, MBChB, FRACP, FRCPA

Blood (2020) 136 (Supplement 1): 33.

https://doi.org/10.1182/blood-2020-140077

Published: 2020

Journal Articles

Epidemiology of Acute Myeloid Leukaemia in New Zealand: A National Cancer Registry Analysis

Henry Chan, MBChB, FRACP, FRCPA, Alana Cavadino, BSc, MSc, PhD, Clinton Lewis, MD

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-136524

Published: 2020

Journal Articles

Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Initial Results of the MAGNOLIA (BGB-3111-214) Trial

Blood (2020) 136 (Supplement 1): 28–30.

https://doi.org/10.1182/blood-2020-134611

Published: 2020

Journal Articles

ME-401-003 (TIDAL): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Phase 2 Study of ME-401 Investigating Continuous and Intermittent Dosing Schedules in Patients with Relapsed/Refractory Follicular Lymphoma

Andrew D. Zelenetz, MD PhD, Pier Luigi Luigi Zinzani, MD, Henry Chan, MBChB, Christian Buske, MD PhD, Vincent Ribrag, David Cunningham, MD FRCP, FMedSci, Wojciech Jurczak, Pau Abrisqueta, MD PhD, Joanne Li, Igor Gorbatchevsky, MD, Jennifer R. Brown, MD PhD

Blood (2019) 134 (Supplement_1): 5244.

https://doi.org/10.1182/blood-2019-124326

Published: 2019

Journal Articles

Targeting B-Cell Maturation Antigen (BCMA) with CC-93269, a 2+1 T Cell Engager, Elicits Significant Apoptosis in Diffuse Large B-Cell Lymphoma Preclinical Models

Patrick R. Hagner, PhD, Michelle Waldman, MS, Falon D. Gray, DVM, DACVP, Renee Yura, PhD, Sarah Hersey, MS, MBA, Henry Chan, PhD, Mingjun Zhang, PhD, Isaac Boss, Anita K Gandhi

Blood (2019) 134 (Supplement_1): 1580.

https://doi.org/10.1182/blood-2019-126115

Published: 2019

Journal Articles

Fixed Dose Carfilzomib Triplets in Lenalidomide Refractory Myeloma

David Simpson, MBChB, FRACP, FRCPA, Henry Chan, MBChB

Blood (2018) 132 (Supplement 1): 3306.

https://doi.org/10.1182/blood-2018-99-110891

Published: 2018

Journal Articles

Single Centre Experience in Treating Elderly Patients with Acute Myeloid Leukaemia or High Risk Myelodysplastic Syndrome with a Combination of Low Dose Cytarabine, Venetoclax and Fluconazole (VeLDAC-F)

Lauren Child, Henry Chan, MBChB, Ross Alistair Henderson, PhD MBChB, Anna Elinder, MBChB, Eileen Merriman, MBChB, Merit Hanna, MBChB, David Simpson, MBChB, FRACP, FRCPA

Blood (2018) 132 (Supplement 1): 5220.

https://doi.org/10.1182/blood-2018-99-115993

Published: 2018

NARROW

Preclinical Characterization of the Anti-Leukemia Activity of the CD33/CD16/NKG2D Immune Modulating TriNKET ® BMS-986357 (CC-96191)

Efficacy and Safety of Single-Agent Zandelisib Administered By Intermittent Dosing in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Final Results of the Tidal Phase 2 Study

Real World Comparison of Treatment Outcomes for Myeloma in Elderly Transplant-Ineligible Population with RVD, RD and VCD in Frontline Setting: Results from Mrdr Australia and New Zealand

Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial

A Phase 1 Study with the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination with Zanubrutinib (ZANU) in Patients (Pts) with Non-Hodgkin Lymphoma (NHL) or Waldenström Macroglobulinemia (WM): Preliminary Data

SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine + Rituximab (BR) in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Discovery and Preclinical Characterization of CC-95251, an Anti-SIRPα Antibody That Enhances Macrophage-Mediated Phagocytosis of Non-Hodgkin Lymphoma (NHL) Cells When Combined with Rituximab

Efficacy and Tolerability of Gemcitabine-Based Chemotherapy in Relapsed/Refractory Lymphoma Patients Not Eligible for Stem Cell Transplant

Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Follow-up Results from Arm C of the SEQUOIA (BGB-3111-304) Trial

Conservative Management of Hemochromatosis without Long-Term Maintenance Venesections in Patients with Moderate Iron Burden

Bortezomib Induction and Consolidation in Patients with Multiple Myeloma Who Received Frontline Autologous Stem Cell Transplant

Epidemiology of Acute Myeloid Leukaemia in New Zealand: A National Cancer Registry Analysis

Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Initial Results of the MAGNOLIA (BGB-3111-214) Trial

ME-401-003 (TIDAL): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Phase 2 Study of ME-401 Investigating Continuous and Intermittent Dosing Schedules in Patients with Relapsed/Refractory Follicular Lymphoma

Targeting B-Cell Maturation Antigen (BCMA) with CC-93269, a 2+1 T Cell Engager, Elicits Significant Apoptosis in Diffuse Large B-Cell Lymphoma Preclinical Models

Fixed Dose Carfilzomib Triplets in Lenalidomide Refractory Myeloma

Single Centre Experience in Treating Elderly Patients with Acute Myeloid Leukaemia or High Risk Myelodysplastic Syndrome with a Combination of Low Dose Cytarabine, Venetoclax and Fluconazole (VeLDAC-F)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only